QJM Advance Access originally published online on September 2, 2009
QJM 2009 102(11):781-784; doi:10.1093/qjmed/hcp118
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Faecal transplant for recurrent Clostridium difficile-associated diarrhoea: a UK case series
From the Infection Unit, Brownlee Centre, Gartnavel General Hospital, Glasgow, UK
Address correspondence to Dr A. MacConnachie, Consultant Physician, Brownlee Centre, Gartnavel General Hospital, 1053 Great Western Road, Glasgow G12 0YN, UK. email: alisdair.macconnachie{at}ggc.scot.nhs.uk
Received 6 November 2008 and in revised form 24 July 2009
 |
Abstract |
|---|
Background: Clostridium difficile-associated diarrhoea (CDAD) is an increasingly common and life threatening consequence of modern medical practice. Recurrent disease is seen in up to one-third of patients and there is no consensus on optimal therapy. Restoration of normal colonic flora addresses the underlying pathogenic mechanism in CDAD.
Methods: We describe the use of nasogastrically administered faecal transplant in the treatment of 15 patients with recurrent CDAD. Retrospective case note review was used to review the success and safety of therapy.
Results: Of 15 patients treated using this technique, 11 were cured of CDAD. Two patients required a further course of metronidazole after transplantation and one patient required a second treatment. One patient had recurrence of CDAD 4 weeks after treatment following a course of broad-spectrum antibiotics. No adverse events were noted.
Conclusion: In our experience, this technique is an effective and safe treatment for recurrent CDAD. Faecal transplantation via a nasogastric tube could be considered in patients with refractory relapsing CDAD.